目的　观察血管紧张素转换酶抑制剂类药物对肾移植后继发性红细胞增多症的治疗效果及安全性。方法　对肾移植后临床诊断为红细胞增多症的 2 4例患者给予血管紧张素转换酶抑制剂类药物治疗 ,用药期间监测患者的血红蛋白、红细胞压积变化及其不良反应。结果　 2 4例中除 1例因低血压停药外 ,其余全部有效 ,起效时间为用药后 7～ 2 0d ;不良反应包括低血压伴头晕 3例 ,血红蛋白≤ 90 g/L 2例 ,肾功能损害 2例。 结论　血管紧张素转换酶抑制剂类药物对肾移植后的红细胞增多症有效 ;用药过程中需监测血、尿常规、血压和肾功能 Objective To observe the therapeutic effect and safety of angiotensin converting enzyme inhibitor on secondary polycythemia after renal transplantation. Methods Twenty-four patients with clinical diagnosis of polycythemia after renal transplantation were treated with angiotensin converting enzyme inhibitors. The hemoglobin, hematocrit changes and adverse reactions were monitored during the treatment. Results Among 24 cases, only 1 patient was stopped due to hypotension, and the rest was effective. The onset time was 7 to 20 days after treatment. The adverse reactions included 3 cases of hypotension with dizziness, 2 cases of hemoglobin ≤ 90 g / L, Functional impairment in 2 cases. Conclusions Angiotensin converting enzyme inhibitors are effective in treating polycythemia after renal transplantation. Blood, urine, blood pressure and renal function